Tag: IFPMA Statement

WHO PAHO 72nd Regional Committee: COVID-19 Pandemic in the Region of the Americas
WHO EURO 70th Regional Committe: The response to the COVID-19 pandemic and lessons learned
WHO AFRO 70th REGIONAL MEETING Agenda item: 6 “Special event on the COVID-19 response in the WHO African Region”
WHO EB 146 Agenda Item 20: Data and innovation: draft global strategy on digital health
EB 144 agenda item 5.5 Universal health coverage
EB 144 agenda item 6.1 Pandemic Influenza Preparedness Framework
EB 144 IFPMA statement under agenda item 5.8.2 Non-Communicable Diseases
EB 144 agenda item 5.7, “Technical” Report on Cancer Pricing
EB 144 IFPMA statement under agenda item 5.7, Access to Medicines and Vaccines Roadmap
R&D-based biopharmaceutical industry welcomes UN Declaration on NCDs
R&D-based biopharmaceutical industry welcomes UN Declaration on TB
WHO WHA 70 agenda item 15.6 Cancer prevention and control in the context of an integrated approach
WHO WHA 70 item 13.6 Member State mechanism on SSFFC
WHO WHA 70 agenda item 13.3 Addressing the global shortage of, and access to, medicines and vaccines
WHO WHA 70 Item A70/12 Antimicrobial resistance
IFPMA Statement on Appointment of Dr Tedros as Director-General of the World Health Organization
WHO EB 140, Item 10.2, Draft global action plan on the public health response to dementia
WHO EB140 agenda item 8.6 Member State mechanism on substandard/spurious/ falsely-labelled/falsified/counterfeit medical products
WHO EB 140, Item 7.4, Public Health implications of the implementation of the Nagoya Protocol
WHO EB 140, Item 8.3, Addressing the global shortage of medicines and vaccines
IFPMA statement on the entry in force of the TRIPS “Paragraph 6” amendment
Extension of TRIPS implementation deadline for LDCs
Adoption of the sustainable development goals (SDGs)
WHA 68, Item 15.1 Antimicrobial resistance
WHA 68, Item 17.3, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products
LDCs request for extension of TRIPS implementation
WHO Executive Board 136 - Item 9.4, 2014 Ebola virus disease outbreak
WHO EB 136, Item 8.1, antimicrobial resistance
WHO EB 136, Item 5.1, Framework of engagement with non-State actors
WHO EB 136, Item 9.3, Global Vaccine Action Plan

Other Tags

Access Access to antiretrovirals Access to Medicines Access to vaccines Africa AMR AMR Industry Alliance Anti-Counterfeit Antibiotics antimicrobial resistance antivirals Biosimilars Biotherapeutic Medicines Biotherapeutics Cancer Clinical Trials Code of Practice collaboration Counterfeit Medicines Counterfeits COVID-19 COVID-19 vaccines Dementia Developing World Diabetes Economic footprint Epidemics Ethics Event Highlights Fake Medicines Fakes Falsified Medicines Fight the Fakes Flu Global Health global health security harmonization Health Health Partnerships HIV/AIDS IFPMA IFPMA Assembly IFPMA Statement Immunization Incremental Innovation Influenza Infographic Infographics Innovation Innovation ecosystem Intellectual Property IP Malaria MDGs Medicines Mental and Neurological Disorders NCDs Neglected Tropical Diseases News Releases Non-Communicable Diseases Novel Coronavirus (COVID-19) NTDs pandemic Pandemic Influenza Pandemic preparedness pandemics partnership Partnerships Pharma Pharmacovigilance Position Paper Prevention Publications Public Health Quality R&D Regulatory regulatory systems Related Links Research Safety SDGs Seasonal Influenza Statements Supply chain Sustainable Development Goals Sustainable Innovation trade Treatments Tuberculosis UHC Universal Health Coverage Vaccine Vaccines Value of Innovation Videos WHA WHO WIPO Women’s Cancers